Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

How nanodiscs could eliminate cancer cells

January 12, 2017 By Danielle Kirsh

The therapeutic cancer vaccine employs nanodiscs (in blue) loaded with tumor neoantigens, which are unique mutations from the patient’s own tumor cells. By generating T-cells to recognize the neoantigens, the nanodiscs can target a patient’s cancer mutations and fight to eliminate cancer cells and prevent tumor growth. [Photo courtesy James Moon, John Gideon Searle]

University of Michigan researchers have successfully developed a cancer vaccine that fights to eliminate colon and melanoma cancer cells and prevent tumor growth in mice.

Nanodiscs loaded with tumor neoantigens deliver a customized therapeutic vaccine targeting cancer mutations. The neoantigens are unique mutations found in tumor cells, and the technology of the nanodiscs recognizes the neoantigens and creates T-cells to fight and eliminate tumors.

“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” said James Moon, assistant professor of pharmaceutical sciences and biomedical engineering at the University of Michigan.

Moon and his team created the nanodiscs out of small, synthetic, high-density lipoproteins that are about 10 nanometers wide (human hair measures 80,000 to 100,000 nm wide). These therapeutic cancer vaccines are made to kill existing cancer cells.

“The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon said.

Michigan researchers tested the nanodisc technology on mice with melanoma and colon cancer, and 27% of the T-cells in the mice blood targeted the tumors. The technology killed tumors within 10 days of being vaccinated in most of the mice, and after 70 days, the immune systems of the mice rejected injected tumor cells, preventing the growth of any new tumors.

Radiation and chemotherapy cancer treatments usually affect the entire body instead of a localized tumor and have a lot of serious side effects. This nanoparticle immunotherapy is fast-growing in the fight against cancer.

“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon said.

The Michigan study is not the first time researchers have been able to kill cancer cells with injectable nanoparticle-generating technology. In 2016, researchers were able to successfully inject the chemotherapy drug doxorubicin straight to the nucleus of metastatic breast cancer cells in mice using an injectable nanoparticle generator (iNPG). Nanoparticles containing the chemotherapy drugs are released from the nanopores of the iNPG once the iNPG reaches the tumor vasculature. This technology was made to increase drug potency and reduce the development of drug resistance in cancer cells.

The nanodisc study was published online in the publication Nature Materials.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

About The Author

Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Related Articles Read More >

May 2025 edition: Inhalable vaccine delivery, type 2 diabetes tech and Medtronic aDBS
A portrait of former Insulet Chief Technology Officer Mark Field.
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ
An image showing the Qfinity+ reusable autoinjector with its hub and a cartridge.
Six sustainable design lessons from the development of a reusable autoinjector
A photo of a woman inhaling a Covid-19 vaccine through an Aerogen nebulizer.
‘Collaborate or die:’ Keys to next-gen inhalable vaccine device design from Aerogen’s R&D director
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe